Effect of half adult dose of oral Rifampicin (300mg) in patientswith idiopathic central serous chorioretinopathy

Khan, Muhammad Saim; Sameen, Murtaza; Lodhi, Arshad Ali; Ahmed, Munawar; Ahmed, Noman; Kamal, Mustafa; Junejo, Sameen Afzal

doi:10.12669/pjms.325.10755

Cited by 8 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Khan et al in their study of 38 eyes in 31 patients prescribed rifampicin 300mg for three months to patients primarily with recent onset CSCR and found that 74% of the patients improved in visual acuity and CMT and also no adverse effects were noted during the study 16. The results in the above study were higher because their 74.2% cases were acute CSCR which usually resolves in 80% of cases without any treatment17,18 but our study included only chronic CSCR and there is significant improvement even after change of regime of the drug.…”

Section: Discussionmentioning

confidence: 96%

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

Loya¹,

Ghoghari²,

Rizvi³

et al. 2019

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To study the effect of reducing the duration of rifampicin therapy in the treatment of Chronic Central Serous Chorioretinopathy. Methods: This is interventional study conducted in Layton Rahmatullah Benevolent Trust, Free Base Eye Hospital Korangi, Karachi from February 2017 - December 2018. This randomized controlled comparative study included two groups, Groups-A comprised of 48 eyes of 40 cases with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 600mg for one month, and Group-B consisted of 43 eyes of 40 controls with Chronic Central Serous Chorioretinopathy who were given reduced dose of oral rifampicin i.e. 300mg once daily for three months as previously stated in literature. To access the effect of therapy in both the groups, pre-treatment visual acuity on the logMAR and Optical Coherent Tomography (OCT, Heidelberg spectralis) for CMT were performed and repeated on the 1st and 3rd month post-treatment. Patients were also followed for 6 months to access any recurrence. Results: On comparing the two groups, Group-A had improvement in VA and CMT after one month therapy of Rifampicin, Pre-treatment mean VA in Group-A was 0.85 ± 0.19 as compared to the pre-treatment mean VA in Group-B i.e. 0.74+/- 0.208, while the pre-treatment mean CMT was 609.0 ± 178.29 µm in Group-A, and 600.0 +/- 155.09 µm in Group-B respectively. After 1 month of therapy, the visual status, and CMT in Group-A was 0.29+/- 0.21 and 311.6 +/- 89.9, while Group-B, VA was 0.598 +/- 0.23 (p value 0.001%) and CMT was 512.30 +/- 148.37 (p-value 0.001%). Rifampicin was continued in Group-B till three months, and patients were re-accessed but there was no difference in VA and CMT statically. During the 3rd and 6th months of follow up no relapses were reported. Conclusion: This comparative study showed that the group receiving oral rifampicin 600mg for one month showed better outcome at one month and third month than the group receiving oral rifampicin at a dose of 300mg once daily for three months. This gives a better compliance and lower the risk of drug induced side effects. doi: https://doi.org/10.12669/pjms.35.6.990 How to cite this:Loya H, Ghoghari H, Rizvi SF, Khan A. Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy. Pak J Med Sci. 2019;35(6):1687-1690. doi: https://doi.org/10.12669/pjms.35.6.990 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 96%

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

Loya¹,

Ghoghari²,

Rizvi³

et al. 2019

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…Some studies have demonstrated efficacy in chronic CSCR; however, these are limited and non-placebo-controlled. 64,65 In contrast, a recent RCT demonstrated no benefit of rifampin for acute CSCR. 66 Any positive effect of rifampin must also be balanced against its known side effect profile that includes hepatotoxicity.…”

Section: Non-pdt Laser Therapymentioning

confidence: 96%

“…Rifampin is a potent inducer of cytochrome P450 enzymes which can modulate the metabolism of endogenous steroids and has been evaluated as a treatment for CSCR. Some studies have demonstrated efficacy in chronic CSCR; however, these are limited and non-placebo–controlled 64,65 . In contrast, a recent RCT demonstrated no benefit of rifampin for acute CSCR 66 .…”

Section: Systemic Topical and Behavioral Therapiesmentioning

confidence: 99%

Update on the Management of Central Serous Chorioretinopathy

Bordbar,

Skrehot,

Weng

2023

International Ophthalmology Clinics

View full text Add to dashboard Cite

“…In addition, Khan et al reported in an observational study on 38 eyes of 31 patients with CSC an improvement in mean BCVA from 0.56 to 0.47 ( p < 0.001) 4 weeks after 300 mg oral rifampicin treatment [ 66 ].…”

Section: Other Oral Pharmacological Treatment Options For Treatingmentioning

confidence: 99%

Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review

et al. 2020

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC) is a common cause of visual impairment in patients generally aged 20 to 60 and it is characterized by acute or chronic neurosensory detachments of the retina. Although CSC resolves spontaneously in most cases, in some patients it may cause permanent visual impairment in the working population; for this reason, several approaches, including photodynamic therapy (PDT), subthreshold micropulse laser treatment and oral mineralocorticoid receptor antagonists, have been studied as first-line treatment options for CSC. To date, half-dose PDT has provided the most encouraging results in this regard, supported by large, multicenter, randomized clinical trials such as the “Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy” (PLACE) trial; however, the role of novel possible non-invasive treatment options is attracting interest. This review article aims to discuss the current pharmacological treatment options investigated for the management of CSC, including aspirin, ketoconazole, beta blockers, rifampicin and many others. In particular, further evidence about oral mineralocorticoid receptor antagonists, firstly seen as promising non-invasive alternatives for treating CSC, will be provided and discussed in light of the recent “Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months” (VICI) trial results, which have largely resized their role as possible first-line oral treatment options for treating CSC.

show abstract

Effect of half adult dose of oral Rifampicin (300mg) in patientswith idiopathic central serous chorioretinopathy

Cited by 8 publications

References 19 publications

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

Effect of altering the regime of oral rifampicin therapy in the treatment of persistent central serous chorioretinopathy

Update on the Management of Central Serous Chorioretinopathy

Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review

Contact Info

Product

Resources

About